CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 235,807	$ 171,945
Marketable securities	317,679	192,648
Trade receivable, net	352,449	308,269
Inventory	106,561	80,608
Prepaid expenses	100,360	88,838
Other current assets	61,485	33,946
Total current assets	1,174,341	876,254
Property and equipment, net	15,727	14,690
Intangible assets, net	75,112	56,438
Other assets	121,069	129,830
Total assets	1,386,249	1,077,212
Current liabilities:
Accounts payable	64,149	51,683
Accrued expenses and other current liabilities	545,307	420,019
Current portion of mandatorily redeemable preferred shares	62,500	62,500
Total current liabilities	671,956	534,202
Long-term debt	764,983	626,720
Liability related to sale of future royalties, net	388,027	367,645
Mandatorily redeemable preferred shares, net	180,213	155,737
Derivative liabilities	110,129	13,110
Obligation to perform R&D services	29,972	50,571
Other long-term liabilities	46,527	12,236
Total liabilities	2,191,807	1,760,221
Commitments and contingencies
Contingently redeemable non-controlling interests	0	60,000
Shareholders’ deficit:
Common shares, no par value; 200,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 71,111,071 and 66,933,531 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	2,181,398	1,676,792
Additional paid-in capital	167,021	169,656
Accumulated other comprehensive loss	(5,811)	(73)
Accumulated deficit	(3,143,541)	(2,585,755)
Total shareholders’ deficit attributable to Biohaven Pharmaceutical Holding Company Ltd.	(800,933)	(739,380)
Non-controlling interests in consolidated subsidiaries	(4,625)	(3,629)
Total shareholders' deficit	(805,558)	(743,009)
Total liabilities and shareholders’ deficit	$ 1,386,249	$ 1,077,212